Global Rice Based Infant Formula Market is expected to reach USD 1,489.68 million by 2026 from USD 992.24 million in 2018, at a CAGR of 5.4% in the forecast period 2019 to 2026. The years considered for study are as mentioned below.
Access Full Report at https://databridgemarketresearch.com/reports/global-rice-based-infant-formula-market/
The rice based infant formula market is an upcoming market which includes key players and local players. The market is growing owing to the favourable market scenario. The market has a prominent growth in upcoming years due to rising population of working mothers, growing infant population, increasing cases of breast cancer and rice based infant formula is widely accepted as non-allergic product.
The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand. For instance, in 2018, BIMBOSAN AG relaunched various products which do not consist of any added sugar. This would help in enhancing the product portfolio of the company and would enhance the customer base of the company.
Danone dominated the rice based infant formula market and accounts for the highest market share in 2018 which is followed by Nestle and Abbott. The other key players existing in the market includes Scientific Brain Nutraceutical Pvt. Ltd., Bellamy's Organic, Bayer, BIMBOSAN AG, BALACTAN NUTRITION S.L., Parent's Choice Infant Formula, SAVENCIA SA, Mead Johnson & Company, LLC. and others.
Danone headquartered in Paris, France was founded in 1919. The company is engaged in offering nutritious and the balanced food products that taste good and also help in delivering health benefits to a wide number of consumers. The company has four business segments namely, essential dairy & plant based international, specialized nutrition, essential dairy & plant based North America and waters. The revenue of the company increased from USD 27,903.59 Million in 2017 to USD 29,170.70 Million in 2018. The specialized nutrition segment delivered a large profitable growth of 5.9% owing to the strong performance of the Advanced Medical Nutrition in adult care and paediatrics and also of the Early Life Nutrition due to a robust growth and contribution from China.
It has its global networks through direct sales representatives and distributors in the Western Europe, Central & Eastern Europe, Americas, Asia-Pacific, Africa-Middle East. The company has various subsidiaries such as Milupa (Germany), Alpro (Belgium), THE WHITEWAVE FOODS COMPANY (U.S.), La Serenísima (Argentina), Danone Japan Co., Ltd. (Japan) amongst others.
Nestle headquartered in Vevey, Switzerland was founded in 1866. The company is mainly engaged in developing the products for food and beverages sector. The company mainly manages their operations through the seven main operating segments such as powdered and liquid beverages, nutrition and health science, milk products and ice cream, petCare, prepared dishes and cooking aids, confectionery and water.
The product related to the rice based infant formula market falls in the nutrition and health science sector. The revenue of the company increased from USD 91,032.00 Million in 2017 to USD 93,366.00 in 2018. There is a significant increase in the sales of nutrition and health science by 6.17% in 2018 as compared to the previous year. The strength of the portfolio in these higher growing categories is due to the strong positions in the emerging markets. The Nestlé Health Science is an added growth platform for the Nestlé and is well positioned for their leadership in consumer care, vitamins, minerals, supplements and medical nutrition.
It has its global networks through direct sales representatives and distributors in Americas, Africa, Europe, Asia and Oceania. It operates through its subsidiaries such as Nestlé Nespresso S.A (Switzerland), Nestlé Purina Petcare (U.S.), Blue Bottle Coffee, Inc. (U.S.), Galderma S.A. (Switzerland), Nestlé Waters (France) and others.
Abbott is headquartered in Illinois, U.S. and founded in 1888. The company is engaged in the manufacturing of products for medical devices, nutrition, diagnostics and branded generic pharmaceuticals. The company operates through different business segments which include established pharmaceuticals, nutritionals, diagnostics, cardiovascular and neuromodulation, and others. The product related to the rice based infant formula market falls in the nutritionals segment.
The nutritionals segment is further classified into pediatric nutritionals and adult nutritionals. Our product mainly falls in pediatric nutritionals. The revenue of nutritionals segment is USD 7,229 Million in 2018 which increased from USD 6,925 Million in 2017 by 4.4%. The sales of nutritional products business are positively impacted by the demographics such as growing rate of the chronic disease in the developed markets and due to the rising middle class in many developing markets and also because of various new product launches that leveraged the Abbott’s strong brands.
The company has wide geographic presence in Americas, Asia-Pacific, Europe, Middle East and South Africa. It operates through its subsidiaries such as Alere Inc.(U.S.), Abbott Medical Optics Inc.(U.S.), EAS (U.S.), Abbott India Ltd (India), Thoratec Corporation (U.S.), Abbott Informatics (U.S.), CardioMEMS (U.S.), CFR Pharmaceuticals (Chile), Abbott GmbH & Co. KG (Germany) among others.
Global Rice Based Infant Formula Market – Industry Trends and Forecast to 2026
Asia-Pacific Rice Based Infant Formula Market – Industry Trends - Forecast to 2026
Europe Rice Based Infant Formula Market – Industry Trends - Forecast to 2026
Middle East and Africa Rice Based Infant Formula Market Industry Trends and Forecast to 2026
North America Rice Based Infant Formula Market – Industry Trends - Forecast to 2026